- Home
- Products
- Customized ADCs
- Adenocarcinoma Antigen
- Anti-Adenocarcinoma antigen (Technetium (99mTc) pintumomab)-MC-MMAF ADC
Anti-Adenocarcinoma antigen (Technetium (99mTc) pintumomab)-MC-MMAF ADC (CAT#: ADC-W-2116)
This ADC product is comprised of an anti-Adenocarcinoma antigen monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- Adenocarcinoma antigen
- Alternative Names
- Adenocarcinoma antigen
- Overview
- Adenocarcinoma is a type of cancerous tumor that can occur in several parts of the body. It is defined as neoplasia of epithelial tissue that has glandular origin, glandular characteristics, or both.
- Overview
- Humanized Anti-Adenocarcinoma antigen IgG1-kappa antibody, Technetium (99mTc) pintumomab
- Generic name
- Technetium (99mTc) pintumomab
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-ERBB2-VCP-cyclooctyne-MMAF ADC (CAT#: ADC-W-176)
- Anti-TNFRSF8 (cAC10)-Mc-PABC-MMAE ADC (CAT#: ADC-W-342)
- Anti-CD33mAb-DOTA-SH ADC (CAT#: ADC-W-360)
- Anti-CD3E (Ertumaxomab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2303)
- Anti-MUC1(clone huC242)-SPDB-DM4 ADC (CAT#: ADC-W-546)
- Anti-KIRD2 (lirilumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2081)
- Anti-PCSK9 (Bococizumab)-SPDB-DM4 ADC (CAT#: ADC-W-2229)
- Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2623)
- Anti-IL12+IL23 (Briakinumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2028)
- Anti-ERBB2 (Trastuzumab)-SPP-DM1 ADC (CAT#: ADC-W-416)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2116. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-2114 | Anti-Adenocarcinoma antigen (Technetium (99mTc) pintumomab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2119 | Anti-Adenocarcinoma antigen (Technetium (99mTc) pintumomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2118 | Anti-Adenocarcinoma antigen (Technetium (99mTc) pintumomab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2115 | Anti-Adenocarcinoma antigen (Technetium (99mTc) pintumomab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2117 | Anti-Adenocarcinoma antigen (Technetium (99mTc) pintumomab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
CAT# | Product Name | Linker | Payload |
ADC-W-478 | Anti-ENPP3-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-114 | Anti-CD33 (clone m2H12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-115 | Anti-CD33 (clone h2H12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-452 | Anti-CD70 (clone 1F6)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
CAT# | Product Name | Linker | Payload |
ADC-W-2591 | Anti-EGFR (Cetuximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2556 | Anti-CD79B (Polatuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2579 | Anti-CEACAM5-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2585 | Anti-EGFR (Zalutumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2550 | Anti-CD74-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.